Introduction
============

Type 1 diabetes (DM1) is a complex disease characterized by the autoimmune destruction of pancreatic *β* cells. Vitamin D is an immune regulatory hormone that exerts its effects through highly polymorphic VDR that belongs to steroid-receptor superfamily, and it is expressed in many cell types such as lymphocytes and antigen-presenting cells (APCs) ([@bib1]). During the last decade, VDR gene polymorphisms have been shown to be associated with autoimmune pathologies ([@bib2]). Vitamin D seems to downregulate type 1 helper (Th-1) cells, by decreasing their proliferation and inhibiting the production of cytokines such as IL-2, TNF-α and interferon-γ ([@bib3], [@bib4]). For many years, the strongest genetic contribution to DM1 susceptibility had been attributed to the presence of human leukocyte antigen region (HLA) on chromosome 6 ([@bib5], [@bib6]). Recently, single nucleotide polymorphisms (SNPs) in the VDR gene have been investigated namely *Fok*I *F* \> *f* (rs10735810), *Bsm*I *B* \> *b* (rs1544410), *Apa*I *A* \> *a* (rs7975232) and *Taq*I t *T* \> *t* (rs731236). Allele F of the *Fok*I SNP creates an alternative ATG initiation codon in exon 2 leading to a three amino acid longer VDR protein. The *Apa*I, *Bsm*I and *Taq*I polymorphisms take place near the 3′ end of the VDR gene; *Bsm*I and *Apa*I SNPs are located in intron 8, and the *Taq*I is a silent SNP in exon 9. Several studies with small data sets that suggested an association between these SNPs and type 1 DM had inconsistent results ([@bib7], [@bib8], [@bib9], [@bib10]). These inconclusive results had been attributed to ethnic diversities among populations or due to the environmental factors involved in type 1 DM pathogenesis. *Bsm*I is strongly linked with 3 poly(A) microsatellite repeat in the 3′ untranslated region, which may influence VDR mRNA stability ([@bib11]). *Bsm*I, *Apa*I and *Taq*I polymorphisms were also designated as polymorphisms without functional effects in several studies ([@bib12], [@bib13]). There are some discrepancies in the literature with small data sets, regarding the relative importance of polymorphisms of VDR genes *Apa*I, *Bsm*I, *Fok*I and *Taq*I. In our meta-analysis, we included a total of 9 studies comprising 1053 patients and 1017 controls that indicated statistically significant associations between DM1 and VDR genotypes, *Bsm*IBB (*P* \< 0.05), *Bsm*IBb (*P* \< 0.05), *Bsm*Ibb (*P* \< 0.05), *Taq*ITT (*P* \< 0.05) and *Taq*Itt (*P* \< 0.05) in children. This present meta-analysis involves a large data set to investigate the associations between type 1 DM and VDR gene polymorphisms *Apa*I, *Bsm*I, *Fok*I and *Taq*I, accordingly demonstrate more reliable statistical results to rule out genotype--phenotype correlation of type 1 DM in children.

Methods
=======

Search strategy criteria
------------------------

For meta-analysis, all published studies evaluating the associations between type 1 DM and *Fok*I, *Apa*I, *Taq*I and *Bsm*I polymorphisms that are investigated in patients diagnosed as DM1 at pediatric age are included. A literature search for the MeSH terms 'type 1 Diabetes mellitus' or 'DM1' was performed by O A, D G and M S Medline, Cochrane and PubMed abstracts were reviewed for relevance. No language and date of study restriction were applied to search strategy. Search to include the eligible studies ended on 05/14/2016. Any study was considered to be eligible for inclusion if it met the following criteria: (1) the publication was an association study of the case control type, (2) at least one of the FokI, ApaI, TaqI and BsmI polymorphism was determined, (3) the outcome was DM in children and (4) there was at least one unrelated control group.

Data extraction
---------------

Study selection and data extraction were performed independently by three authors (O A, D G and M S) based on a customized database for extraction. For each study, the following information was collected: first author, year and location of the study, average age at the time of diagnosis, ethnicity, number of participants, number of cases and controls and number of the genotypes in cases and controls. The disagreements were resolved between the reviewers by consensus. For quality assessment, six domains were assessed. Those were representativeness of classes, representativeness of the controls, ascertainment of DM1, genotypic examination and association of assessment. The primary outcome considered in the meta-analysis was the association between DM1 and the presence of *Fok*I, *Apa*I, *Taq*I or *Bsm*I polymorphism at pediatric age. For the primary analysis and to allow appropriate comparison of all studies, cases and controls were classified based on *Fok*I, *Apa*I, *Taq*I and *Bsm*I genotypes.

Statistical analysis
--------------------

The odds ratios (OR) with 95% confidence intervals, representativeness of controls, ascertainment of DM1, ascertainment of controls, genotypic examination and association assessments were done. The primary outcome considered in the meta-analysis was the association between DM1 and the presence of FokI, ApaI, TaqI or BsmI polymorphisms. MedCalc Software Acacialaan 22, 8400 (Ostend, Belgium) was used to perform meta-analysis. The odds ratios (OR) of the genetic polymorphisms were combined and calculated, and the funnel plots were drawn. All of the four studied SNPs (*FokI*, *ApaI*, *TaqI* and *BsmI*) were diallelic, and we calculated summary odds ratios incorporating both within- and between-study variation using a random effects model proposed by DerSimonian and Laird ([@bib14]).

Results
=======

Our search yielded a total of 50 references. After screening the titles and abstracts, 41 studies were excluded because they were not considered relevant to the study topic, leaving 9 potentially eligible studies ([Fig. 1](#fig1){ref-type="fig"}) ([@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23]). Figure 1Flow chart for identification and selection of studies.

In the 9 published papers included in the meta-analysis, *Apa*I, *Bsm*I, *Fok*I and *Taq*I polymorphisms were investigated in pediatric population as case--control studies ([Table 1](#tbl1){ref-type="table"}). Table 1Characteristics features of studies included in the meta-analysis of *Apa*I, *Bsm*I, *Fok*I and *Taq*I polymorphisms in the vitamin D receptor gene.First authorYearRegion**Mean age of cases/diagnosis** (years)Cases**Source of controlsMean age of controls** (years)ControlsDiego Garcia2007Santiago-Chile9.3 ± 4.2216Unrelated children10.3 ± 2.5203J I San Pedro2005Bilbao-Spain14.5 ± 9.971Healthy blood donors88Tatijana Semunik2005Split-Croatia8.6 ± 4.3132Unrelated children8.2 ± 4.9232Vaselin Scrabic2003Split-Croatia8.6 ± 4.3134Unrelated children8.24 ± 4.9132Balazs Gyorffy2002Budapest-Hungary5.8 ± 3.2107Healthy blood donors103Tien-Jyung Chang2000Han Chinese-Taiwan8.8 ± 5.6157Healthy subjects248Charalambos Panierakis2009Crete-GreeceChildren100Unrelated children96Greear R M2013Brisbane-Australia\<1555Healthy subjects\<1550Chong-Kun Cheon2015Pusan-South Korea10.28 ± 3.2381Healthy children9.98 ± 3.56113

Eight studies on the ApaI-type 1 diabetes association recruited 921 cases/patients and 1033 controls, whereas seven studies on the BsmI polymorphism recruited 866 cases and 983 controls. For the FokI polymorphism, five studies included 465 cases and 569 controls, whereas eight studies on the TagI polymorphism included 921 cases and 1033 controls. Individual and pooled odds ratio estimates of four single-nucleotide polymorphisms in the vitamin receptor gene, *P* values testing Hardy--Weinberg proportion, test for heterogeneity ([Tables 2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}, [5](#tbl5){ref-type="table"}, [6](#tbl6){ref-type="table"}, [7](#tbl7){ref-type="table"}, [8](#tbl8){ref-type="table"}, [9](#tbl9){ref-type="table"}, [10](#tbl10){ref-type="table"}, [11](#tbl11){ref-type="table"}, [12](#tbl2){ref-type="table"} and [13](#tbl13){ref-type="table"}) and funnels plots ([Figs 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) are documented for BsmI and TaqI, respectively. Figure 2(A, B and C) Forest plots showing individual and pooled odds ratio estimates of *BsmI BB*, *BsmI Bb*, *BsmIbb* polymorphisms, respectively. Figure 3(A and B) Forest plots showing individual and pooled odds ratios of TaqITT and TaqItt polymorphisms, respectively. Table 2*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *ApaI* AA polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 200016/15713/2482.0510.958--4.391Balazs Gyorffy 200233/10723/1031.5510.835--2.881Vaselin Scrabic 200366/13451/1321.5420.947--2.509J J San Pedro 200515/7128/880.5740.278--1.185Diego Garcia 200754/21643/2031.2400.786--1.957C Panierakis 200923/10037/960.4760.256--0.886Greear R M 201315/5512/501.1870.493--2.861Chung Cheon 20155/819/1130.7600.245--2.359Total (fixed effects)227/921216/10331.1130.893--1.3880.9540.340Total (random effects)227/921216/10331.0810.755--1.5470.4250.671Q16.3471DF7Significance level*P* = 0.0221*I*^2^ (inconsistency)57.18%95% CI for *I*^2^5.93--80.51[^1][^2] Table 3*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for ApaI Aa polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 200076/157105/2481.2780.855--1.910Balazs Gyorffy 200245/10754/1030.6590.382--1.136Vaselin Scrabic 200352/13466/1320.6340.390--1.032J J San Pedro 200537/7143/881.1390.609--2.129Diego Garcia 2007115/216125/2030.7100.481--1.048C Panierakis 200958/10057/960.9450.535--1.669Greear R M 201324/5532/500.4350.198--0.956Chung Cheon 201532/8134/1131.5170.833--2.765Total (fixed effects)439/921516/10330.8730.729--1.046−1.4730.141Total (random effects)439/921516/10330.8660.664--1.131−1.0540.292Q14.2512DF7Significance level*P* = 0.0469*I*^2^ (inconsistency)50.88%95% CI for *I*^2^0.00--78.02[^3][^4] Table 4*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for ApaI aa polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 200065/157130/2480.6410.428--0.960Balazs Gyorffy 200227/10726/1031.0000.536--1.863Vaselin Scrabic 200316/13415/1321.0580.500--2.238J J San Pedro 200519/7117/881.5260.724--3.217Diego Garcia 200744/21635/2031.2280.751--2.009C Panierakis 200915/1006/962.6470.982--7.139Greear R M 201311/5511/500.8860.346--2.270Chung Cheon 201544/8170/1130.7310.409--1.304Total (fixed effects)241/921310/10330.9560.772--1.182−0.4190.675Total (random effects)241/921310/10331.0050.754--1.3390.03490.972Q11.2531DF7Significance level*P* = 0.1280*I*^2^ (inconsistency)37.79%95% CI for *I*^2^0.00--72.53[^5][^6] Table 5*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *BsmI BB* polymorphism, respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 20004/1571/2486.4580.715--58.314Balazs Gyorffy 200217/10719/1030.8350.407--1.713Vaselin Scrabic 200324/13417/1321.4760.752--2.896J J San Pedro 200515/7117/881.1190.514--2.435Diego Garcia 200721/21614/2031.4540.718--2.943C Panierakis 200938/10023/961.9451.048--3.611Chung Cheon 20150/811/1130.4600.0185--11.440Total (fixed effects)119/86692/9831.3971.034--1.8882.1740.030Total (random effects)119/86692/9831.3861.021--1.8802.0920.036Q5.7387DF6Significance level*P* = 0.4531*I*^2^ (inconsistency)0.00%95% CI for *I*^2^0.00--69.98[^7][^8] Table 6*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *BsmI Bb* polymorphism, respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Chang 200016/15716/2481.6450.798--3.393Balazs Gyorffy 200253/10744/1031.3160.764--2.268Vaselin Scrabic 200358/13474/1320.5980.368--0.971J J San Pedro 200540/7144/881.2900.688--2.418Diego Garcia 2007110/21674/2031.8091.224--2.674C Panierakis 200943/10023/962.3941.296--4.422Chung Cheon 201513/814/1135.2101.632--16.633Total (fixed effects)333/866279/9831.4301.160--1.7623.3470.001Total (random effects)333/866279/9831.5341.001--2.3501.9660.049Q21.6238DF6Significance level*P* = 0.0014*I*^2^ (inconsistency)72.25%95% CI for *I*^2^40.02--87.16[^9][^10] Table 7*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *BsmI bb* polymorphism, respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 2000137/157231/2480.5040.255--0.995Balazs Gyorffy 200235/10740/1030.7660.435--1.348Vaselin Scrabic 200352/13441/1321.4070.848--2.336J J San Pedro 200516/7127/880.6570.321--1.347Diego Garcia 200777/216115/2030.4240.286--0.628C Panierakis 200915/10020/960.6710.321--1.402Chung Cheon 201568/81108/1130.2420.0826--0.710Total (fixed effects)400/866582/9830.6320.508--0.786−4.114\<0.001Total (random effects)400/866582/9830.6240.418--0.933−2.2980.022Q17.5208DF6Significance level*P* = 0.0075*I*^2^ (inconsistency)65.76%95% CI for *I*^2^23.26--84.72[^11][^12] Table 8*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *FokI FF* polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Balazs Gyorffy 200236/10729/1031.2940.719--2.328Tatijana Semunik 200542/13273/2321.0160.642--1.609J J San Pedro 200531/7141/880.8880.474--1.666C Panierakis 200964/10050/961.6360.923--2.898Greear R M 201321/5528/500.4850.223--1.058Total (fixed effects)194/465221/5691.0570.817--1.3670.4200.675Total (random effects)194/465221/5691.0360.733--1.4650.2020.840Q6.8448DF4Significance level*P* = 0.1443*I*^2^ (inconsistency)41.56%95% CI for *I*^2^0.00--78.48[^13][^14] Table 9*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *FokI Ff* polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Balazs Gyorffy 200249/10756/1030.7090.412--1.221Tatijana Semunik 200563/132136/2320.6450.419--0.991J J San Pedro 200535/7139/881.2220.652--2.287C Panierakis 200931/10043/960.5540.309--0.993Greear R M 201321/5522/500.7860.361--1.714Total (fixed effects)199/465296/5690.7240.564--0.929−2.5380.011Total (random effects)199/465296/5690.7230.563--0.929−2.5350.011Q3.8098DF4Significance level*P* = 0.4324*I*^2^ (inconsistency)0.00%95% CI for *I*^2^0.00--79.45[^15][^16] Table 10*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for *FokI ff* polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Balazs Gyorffy 200222/10718/1031.2220.612--2.441Tatijana Semunik 200529/13223/2322.5581.410--4.643J J San Pedro 20055/718/880.7580.237--2.426C Panierakis 20091/1007/960.1280.0155--1.064Greear R M 20137/555/501.3120.388--4.435Total (fixed effects)64/46561/5691.3740.943--2.0031.6560.098Total (random effects)64/46561/5691.1590.573----2.3440.4110.681Q10.1246DF4Significance level*P* = 0.0384*I*^2^ (inconsistency)60.49%95% CI for *I*^2^0.00--85.20[^17][^18] Table 11*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for TaqITT polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Chang 2000142/157233/2480.6090.289--1.284Balazs Gyorffy 200244/10742/1031.0140.585--1.759Vaselin Scrabic 200354/13448/1321.1810.720--1.938J J San Pedro 200524/7131/880.9390.486--1.813Diego Garcia 2007115/216121/2030.7720.524--1.137C Panierakis 200910/10034/960.2030.0933--0.440Greear R M 201318/5526/500.4490.204--0.990Chung Cheon 201566/81105/1130.3350.135--0.834Total (fixed effects)473/921640/10330.7130.580--0.876−3.2130.001Total (random effects)473/921640/10330.6440.440--0.942−2.2700.023Q20.6282DF7Significance level*P* = 0.0044*I*^2^ (inconsistency)66.07%95% CI for *I*^2^28.03--84.00[^19][^20] Table 12*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for TaqITt polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***Chang 200015/15714/2481.7660.828--3.766Balazs Gyorffy 200228/10733/1030.7520.414--1.367Vaselin Scrabic 200355/13472/1320.5800.357--0.943J J San Pedro 200536/7143/881.0760.576--2.012Diego Garcia 200779/21669/2031.1200.750--1.673C Panierakis 200964/10059/961.1150.625--1.990Greear R M 201326/5524/500.9710.451--2.091Chung Cheon 201515/818/1132.9831.199--7.423Total (fixed effects)318/921322/10331.0170.829--1.2480.1650.869Total (random effects)318/921322/10331.0620.785--1.4380.3900.697Q13.8658DF7Significance level*P* = 0.0536*I*^2^ (inconsistency)49.52%95% CI for *I*^2^0.00--77.47[^21][^22] Table 13*P* values testing Hardy--Weinberg proportion and test for heterogeneity of studies included in the meta-analysis for TaqItt polymorphism respectively.**StudyInterventionControlsOdds ratio95% CI*z**P***T J Chang 20000/1571/2480.5240.0212--12.939Balazs Gyorffy 200233/10726/1031.3210.721--2.418Vaselin Scrabic 200325/13411/1322.5231.186--5.367J J San Pedro 200511/7114/880.9690.410--2.290Diego Garcia 200722/21613/2031.6570.811--3.386C Panierakis 200922/1007/963.5861.453--8.849Greear R M 20136/555/501.1020.314--3.862Chung Cheon 20150/810/113--Total (fixed effects)119/92177/10331.6771.225--2.2953.2300.001Total (random effects)119/92177/10331.6551.163--2.3562.7980.005Q6.9433DF6Significance level*P* = 0.3261*I*^2^ (inconsistency)13.59%95% CI for *I*^2^0.00--75.19[^23][^24]

Of the articles included in the study, investigators of all studies included in the meta-analysis specifically looked for the presence of autoantibodies to diagnose type 1 diabetes and all fulfilled World Health Organization and the American Diabetes Association criteria ([@bib24]).

Selection of controls varied across studies. Groups of controls included healthy blood donors and unrelated children.

ApaI, BsmI, FokI and TaqI polymorphisms and the risk for type 1 diabetes
------------------------------------------------------------------------

For ApaI-AA, the odds ratio ranged from 0.476 to 2.051 ([Table 2](#tbl2){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 1.081 (95 percent confidence interval (CI): 0.755--1.547). There was indication of heterogeneitiy (*P* = 0.0221).

For ApaI-Aa, the odds ratio ranged from 0.435 to 1.517 ([Table 3](#tbl3){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 0.866 (95 percent confidence interval (CI): 0.664--1.131). There was indication of heterogeneity (*P* = 0.0469).

For ApaI-aa, the odds ratio ranged from 0.641 to 2.647 ([Table 4](#tbl4){ref-type="table"}). The fixed-effects model yielded a pooled odds ratio of 0.956 (95 percent confidence interval (CI): 0.772--1.182). There was indication of homogeneity (*P* = 0.1280). In view of these estimates, there is no evidence that any of the three alleles alone is associated with type 1 diabetes.

For BsmI-BB, the odds ratio ranged from 0.460 to 6.458 ([Table 5](#tbl5){ref-type="table"}). The fixed-effects model yielded a pooled odds ratio of 1.397 (95 percent confidence interval (CI): 1.034--1.888, *P* = 0.030). There was indication of homogeneity (*P* = 0.4531).

For BsmI-Bb, the odds ratio ranged from 0.598 to 5.210 ([Table 6](#tbl6){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 1.534 (95 percent confidence interval (CI): 1.001--2.350, *P* = 0.049). There was indication of heterogeneity (*P* = 0.0014).

For BsmI-bb, the odds ratio ranged from 0.242 to 1.407 ([Table 7](#tbl7){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 0.624 (95 percent confidence interval (CI): 0.418--0.933, *P* = 0.022). There was indication of heterogeneity (*P* = 0.0075).

Forest plots are shown in [Fig. 2A](#fig2){ref-type="fig"}, [B](#fig2){ref-type="fig"} and [C](#fig2){ref-type="fig"} for BsmI BB, Bb and bb alleles, respectively. Individual and pooled odds ratio estimates for the BsmI alleles are represented as squares and diamonds. In view of these estimates, there is evidence that BsmI-Bb or BsmI-bb alone is associated with type 1 diabetes.

For FokI-FF, the odds ratio ranged from 0.485 to 1.636 ([Table 8](#tbl8){ref-type="table"}). The fixed-effects model yielded a pooled odds ratio of 1.057 (95 percent confidence interval (CI): 0.817--1.367, *P* = 0.675). There was indication of homogeneity (*P* = 0.1443).

For FokI-Ff, the odds ratio ranged from 0.645 to 1.222 ([Table 9](#tbl9){ref-type="table"}). The fixed-effects model yielded a pooled odds ratio of 0.724 (95 percent confidence interval (CI): 0.564--0.929, *P* = 0.011). There was indication of homogeneity (*P* = 0.4324).

For FokI-ff, the odds ratio ranged from 0.128 to 2.558 ([Table 10](#tbl10){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 1.159 (95 percent confidence interval (CI): 0.573--2.344, *P* = 0.681). There was indication of heterogeneity (*P* = 0.0384).

For TagI-TT, the odds ratio ranged from 0.203 to 1.181 ([Table 11](#tbl11){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 0.644 (95 percent confidence interval (CI): 0.440--0.942, *P* = 0.023). There was indication of heterogeneity (*P* = 0.0044).

For TaqI-Tt, the odds ratio ranged from 0.580 to 2.983 ([Table 12](#tbl12){ref-type="table"}). The random-effects model yielded a pooled odds ratio of 1.062 (95 percent confidence interval (CI): 0.785--1.438, *P* = 0.697). There was some indication of heterogeneity (*P* = 0.0536).

For TaqI-tt, the odds ratio ranged from 0.524 to 3.586 ([Table 13](#tbl13){ref-type="table"}). The fixed-effects model yielded a pooled odds ratio of 1.655 (95 percent confidence interval (CI): 1.677--2.295, *P* = 0.001). There was indication of heterogeneity (*P* = 0.3261).

Forest plots are shown in [Fig. 3](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"} for TaqI-TT and tt alleles, respectively. Individual and pooled odds ratio estimates for the TaqI alleles are represented as squares and diamonds. In view of these estimates, there is evidence that TaqI-TT and TaqI-tt alone is associated with type 1 diabetes.

Discussion
==========

There are a number of reports on *Fok*I, *Apa*I, *Taq*I and *Bsm*I polymorphisms of the VDR gene in diabetic patients, there have not been conclusive evidence that any of these polymorphisms has causative association with type 1 DM in children. In a 2006 meta-analysis that focused on VDR polymorphisms, FokI, ApaI, TaqI, BsmI and type 1 DM association included mainly adult samples and did not reveal any specific association ([@bib25]). However, out of 19 published papers included in this meta-analysis, authors of only five papers specifically looked for the presence of autoantibodies to distinguish type 1 diabetes from type 2. In other 14 studies included in this meta-analysis, investigators used only one criteria (e.g., ketosis, early requirement of insulin). This may be one of the main reasons for different statistical results other than ethnic diversities when compared to our results. DM1 is mainly a disease of pediatric age: considering the qualitative assessment of study inclusion criteria, choosing studies where diagnosis is at pediatric age with age matching control samples, and/or taking American Diabetes Association criteria would end up with more reliable meta-analysis results. In our study, mean age of control samples are in pediatric range. In another meta-analysis involving Chinese adult samples, authors concluded that BsmI polymorphisms in the VDR region would increase the risk of type 1 DM in East Asians ([@bib26]). In the study of Zhang J, Asian samples with BsmI polymorphism was found to have a significant association with increased risk of type 1 DM ([@bib27]). The study of Qin WH demonstrated a significant relationship among BsmI B allele and BB genotype and increased risk for type 1 DM in Asians, whereas this study included Latino and African adult samples and authors also found another specific association with BsmIbb genotype and type 1 DM in overall populations ([@bib28]). The novel finding in our study was the presence of an increased risk of type 1 DM in carriers of *Bsm*IBB, *Bsm*IBb and *Taq*Itt polymorphisms and decreased risk of type 1 DM in children with *Bsm*Ibb and *Taq*ITT polymorphisms. There are GWAS studies that widen our approach to vitamin D receptor polymorphisms and DM1.

Meta-analysis may be more reliable when evaluating genotype frequencies in certain diseases because in a way it may reduce the effect of biased sampling or nonrandom mating in individual study population. Results of studies so far, regarding VDR polymorphisms and DM1 susceptibility, are conflicting. In the study of Garcia and coworkers, an association was found between BsmI polymorphism and DM1 ([@bib15]). The frequency of genotype bb was found to be significantly lower in the cases than that in controls. Among five prevalent haplotypes, BAT has been found to be statistically more frequent in study group in the same study. Among genotype combinations, AabbTT was found to be higher in controls. In our study population, genotype combination frequencies were not assessed because of unavailable data, and this may be one of the limitations of our study.

In the study of San-Pedro JI, an association of an haplotype 'fBAt' and risk of type 1 DM in Basque population has been identified ([@bib16]). In the study of Skrabic V, BBAAtt genotype combination was found to be associated with type 1 DM in Dalmatian population of southern Croatia, with the 'tt' genotype preferentially presented in the affected individuals ([@bib17]). This was also noticed in previous studies that focused on association of VDR gene polymorphisms with increased susceptibility to T1DM in Taiwanese, Japanese, South Asian (Indian) and German populations ([@bib29], [@bib30], [@bib31], [@bib32]). *Taq*I polymorphism among type 1 DM patients and control subjects differed significantly, with the VDR tt genotype occurring more frequently in T1DM patients. No difference was noticed in the genotype frequencies of BsmI and ApaI polymorphisms in cases and controls. We evaluated *Taq*Itt polymorphism frequency and demonstrated a significant increase in diabetic children in our study. In the study of Zemunik and coworkers, some evidence of association of Tru91--BsmI haplotype and type 1 DM in population of South Croatia was found ([@bib17]). In our meta-analysis, we have included two studies from Croatia. One of the limitations of this study was that its sample size was small, it only included nine studies and the power of this study is not high. In the study of Panierakis and coworkers, homogeneous southern European population with low incidence of type 1 DM was included in the study group, and they found an association of T1DM and *Fok*I, *Bsm*I, *Apa*I and *Taq*I polymorphisms. In this study, *Fok*IFF genotype and F allele and *Bsm*IBB genotype and B allele were less frequent in individuals with T1DM ([@bib21]). In the same study, *Apa*IAA genotype and A allele, as well as *Taq*ITT genotype and T allele were more frequent in individuals. Greear and coworkers also studied the association of *Taq*1, *Fok*1, *Apa*1 and type 1 DM and found no significant difference in distribution of VDR polymorphisms in diabetic patients, whereas diabetic patients had significantly decreased levels of vitamin D levels than healthy controls ([@bib22]). In the study of Cheon CK and coworkers, the frequency of bb and TT genotype has been found to be significantly increased among carriers demonstrating a protective effect in Korean subjects ([@bib23]). Gyorffy and coworkers suggested a strong linkage disequilibrium between the 'b' and 'a' alleles in his study. The close loci of these polymorphisms might be an explanation for the stability of linkage, but the background of these combinations need further investigation ([@bib19]). In the same study, a strong association has been found between carrier state of the 'b' + 'a' + 'u' alleles and the presence of type 1 DM in females. There are other reports as well that point out to a gender-specific association and consequence of gene polymorphism ([@bib33]). A number of studies have shown that patients with 1 DM have low levels of vitamin D although other studies have conflicting results ([@bib34], [@bib35], [@bib36]). In 2010, GWAS study in approximately 30,000 individuals from European descent identifies variants at four loci that were associated with 25(OH)D levels: GC rs2282679, dhcr7 RS 12785878 and CYP2R1 ([@bib37]). A second GWAS of 25(OH)D levels confirmed the findings with GC, DHCR7 and CYP2R1 ([@bib38]). These variants are located within or near genes involved in vitamin D transport (GC), cholesterol synthesis (DHCR7) and hydroxylation (CYP2R1 and CTP24A1) ([@bib37]). Cooper and coworkers recently tested genetic variants influencing 25(OH)D metabolism for an association with both circulating 25(OH)D metabolism for an association with both circulating 25(OH)D concentrations and T1D. They replicated the associations found in the GWAS of the four vitamin D metabolism genes (GC, DHCR7, CYP2R1 and CYP24A1) with 25(OH)D in control subjects and found that CYP27B1, DHCR7 and CYP2R1 were associated with type 1 diabetes ([@bib39]). The Fok1 polymorphism of the VDR, which increases the transcriptional activity of VDR, has been suggested as an influencing factor for susceptibility to T1DM. It affects insulin secretion and sensitivity and has been found to be a susceptibility factor for the development of diabetic retinopathy ([@bib40], [@bib41]). In addition, vitamin D-binding protein gene polymorphisms were found to be associated with diabetes-associated antibody insulinoma antigen 2 and with T1DM ([@bib42]). In the study of Greear and coworkers, low vitamin D levels in the diabetic children have been attributed to inflammatory or other pathologic processes, mainly as a consequence of the disease rather than being a risk factor, as previously stated in DAISY study ([@bib43]). In the study of Chang and coworkers, the allele frequency of the BsmI differed between Taiwanese patients and controls significantly ([@bib20]). There are some limitations in this meta-analysis. The power of this study should further be increased by additional studies, and this meta-analysis involves only nine studies. Some of the studies contained small number of cases, and background of the patients varied across included studies. However our meta-analysis employed a random-effects model designed to encounter these variations and found significant effect of polymorphisms on type 1 DM susceptibility.

As a conclusion, our meta-analysis of accessible published data has demonstrated statistically significant association between BsmIBB, BsmIBb, BsmIbb, *Taq*ITT and Taqtt polymorphisms and susceptibility to type 1 DM in children; however, influence of vitamin D receptor gene polymorphisms on susceptibility to type 1 diabetes deserves further investigations. Meta-analysis includes larger data sets and accordingly may demonstrate more reliable statistical results to rule out genotype--phenotype correlations of diseases.
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[^1]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.142857 *P* = 0.5484 (low power); Egger: bias = −1.369742 (95% CI = −6.646958 to 3.907474) *P* = 0.5488; Harbord--Egger: bias = −1.179831 (92.5% CI = −5.949539 to 3.589877) *P* = 0.6138.

[^2]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^3]: Bias indicators: Begg--Mazumdar: Kendall's Tau = 0 *P* = 0.9049 (low power); Egger: bias = −0.928241 (95% CI = −7.113964 to 5.257482) *P* = 0.7261; Harbord--Egger: bias = −0.806491 (92.5% CI = −6.321591 to 4.708608) *P* = 0.7638.

[^4]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^5]: Bias indicators: Begg--Mazumdar: Kendall's Tau = 0.428571 *P* = 0.1789 (low power); Egger: bias = 2.766246 (95% CI = −0.351565 to 5.884058) *P* = 0.073; Harbord--Egger: bias = 2.78392 (92.5% CI = −0.118976 to 5.686817) *P* = 0.0847.

[^6]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^7]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.333333 *P* = 0.2389 (low power); Egger: bias = 0.081309 (95% CI = −2.562044 to 2.724662) *P* = 0.94; Harbord--Egger: bias = 0.057432 (92.5% CI = −2.538737 to 2.653601) *P* = 0.9624.

[^8]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^9]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.333333 *P* = 0.3813 (low power); Egger: bias = 2.518064 (95% CI = −4.133965 to 9.170093) *P* = 0.3752; Harbord--Egger: bias = 2.595692 (92.5% CI = −3.668787 to 8.860172) *P* = 0.3955.

[^10]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^11]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.142857 *P* = 0.5619 (low power); Egger: bias = −0.656941 (95% CI = −7.053883 to 5.74) *P* = 0.8023; Harbord--Egger: bias = 0.561504 (92.5% CI = −6.312289 to 5.189281) *P* = 0.8354.

[^12]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^13]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.6 *P* = 0.00833 (low power); Egger: bias = −3.653382 (95% CI = −14.60785 to 7.301086) *P* = 0.3664; Harbord--Egger: bias = −3.796013 (92.5% CI = −13.262673 to 5.670648) *P* = 0.3612.

[^14]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^15]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.4 *P* = 0.4833 (low power); Egger: bias = 1.95378 (95% CI = 5.613844--9.521404) *P* = 0.4715; Harbord--Egger: bias = 2.01803 (92.5% CI = −4.313428 to 8.349488) *P* = 0.4557.

[^16]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^17]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.6 *P* = 0.0833 (low power); Egger: bias = −3.173487 (95% CI = −6.536026 to 0.189052) *P* = 0.575; Harbord--Egger: bias = −4.109035 (92.5% CI = −8.5417147 to 0.323644) *P* = 0.0889.

[^18]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^19]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.642857 *P* = 0.0141 (low power); Egger: bias = −3.773452 (95% CI = −8.197852 to 0.650947) *P* = 0.0819; Harbord--Egger: bias = −3.522136 (92.5% CI = −8.048273 to 1.004) *P* = 0.1452.

[^20]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^21]: Bias indicators: Begg--Mazumdar: Kendall's Tau = 0.047619 *P*  \> 0.9999 (low power); Egger: bias = 1.307065 (95% CI = −4.196619 to 6.810748) *P* = 0.5682; Harbord--Egger: bias = 1.410342 (92.5% CI = −3.284733 to 6.105417) *P* = 0.5305.

[^22]: DF, degree of freedom; Q, heterogeneity in meta analysis.

[^23]: Bias indicators: Begg--Mazumdar: Kendall's Tau = −0.047619 *P*  \> 0.9999 (low power); Egger: bias = −6.680722 (95% CI = −3.88097 to 2.519525) *P* = 0.608; Harbord--Egger: bias = −1.122847 (92.5% CI = −3.907446 to 1.661601) *P* = 0.4074.

[^24]: DF, degree of freedom; Q, heterogeneity in meta analysis.
